Search results
Showing 1 to 4 of 4 results for inotersen
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
NICE has withdrawn this guidance. Sobi will stop marketing inotersen (Tegsedi) because its no longer available in the UK. Healthcare professionals should discuss alternative treatment options with people currently having inotersen.
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.